PTEN and exanthem: TTP and OS to the ≥2nd line cetuximab-containing treatment according to KRAS, BRAF, PIK3CA mutations status, PTEN protein expression, AREG and EREG mRNA expression and grade of skin rash in the whole patient′ population.